Avatrombopag for treating primary chronic immune thrombocytopenia

2.1 Avatrombopag (Doptelet, Swedish Orphan Biovitrum) is 'indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g., corticosteroids or immunoglobulins)'.

2.2 The dosage schedule is available in the summary of product characteristics for avatrombopag.

2.3 The list price of a 10‑tablet pack of avatrombopag 20 mg is £640.00 (excluding VAT; BNF online, accessed June 2022).

2.4 The company has a commercial arrangement. This makes avatrombopag available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.